• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新辅助治疗扩大肝转移的演变——我们是否已经达到（不可切除）极限？

Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?

机构信息

AP-HP Hospital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.

出版信息

J Surg Oncol. 2010 Dec 15;102(8):922-31. doi: 10.1002/jso.21727.

DOI:10.1002/jso.21727
PMID:21165994
Abstract

Surgical resection offers the best chance for cure in patients with colorectal liver metastases; however, only 15-25% of them can benefit from surgery. To increase resectability a number of strategies have been developed in different fields including chemotherapy, surgery, and radiology. Bringing them together into an integrated framework has expanded the number of patients that can be treated with curative intent. This review focuses on recent oncosurgical changes, their impact, and future directions.

摘要

手术切除为结直肠肝转移患者提供了治愈的最佳机会；然而，只有 15-25%的患者可以从手术中受益。为了提高可切除性，已经在化疗、手术和放射学等不同领域开发了许多策略。将它们整合到一个综合框架中，扩大了可以治愈的患者数量。本文综述了最近的肿瘤外科变化、其影响和未来方向。

相似文献

1
Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?新辅助治疗扩大肝转移的演变——我们是否已经达到（不可切除）极限？
J Surg Oncol. 2010 Dec 15;102(8):922-31. doi: 10.1002/jso.21727.
2
Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials.结直肠癌肝转移的新辅助治疗：来自临床试验的经验教训。
J Surg Oncol. 2010 Dec 15;102(8):932-6. doi: 10.1002/jso.21657.
3
Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy.新辅助化疗后“应答”性肝转移的优化切除。
J Surg Oncol. 2010 Dec 15;102(8):1002-8. doi: 10.1002/jso.21694.
4
[Colorectal cancer liver metastases -- neoadjuvant concepts for preoperative down-sizing].[结直肠癌肝转移——术前缩小肿瘤体积的新辅助治疗理念]
Zentralbl Chir. 2006 Apr;131(2):140-7. doi: 10.1055/s-2006-921538.
5
[Oncosurgical strategies for metastatic liver cancer].[转移性肝癌的肿瘤外科治疗策略]
Cir Esp. 2011 Jan;89(1):10-9. doi: 10.1016/j.ciresp.2010.10.007. Epub 2010 Dec 21.
6
Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases.结直肠癌肝转移新辅助化疗的最佳化疗方案。
J Surg Oncol. 2010 Dec 15;102(8):946-54. doi: 10.1002/jso.21653.
7
[Timing of resection in patients with colorectal carcinoma and synchronous liver metastases].[结直肠癌伴同时性肝转移患者的手术时机]
Zentralbl Chir. 2009 Sep;134(5):425-9. doi: 10.1055/s-0029-1224612. Epub 2009 Sep 15.
8
Resection and local therapy for liver metastases.肝转移瘤的切除术及局部治疗
Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):299-317. doi: 10.1053/bega.2002.0286.
9
[Neoadjuvant chemotherapy as a treatment strategy for multiple bilobar liver metastases from colorectal carcinoma].[新辅助化疗作为结直肠癌多发双侧肝转移的治疗策略]
Nihon Geka Gakkai Zasshi. 2006 May;107(3):128-32.
10
Making unresectable hepatic colorectal metastases resectable--does it work?使无法切除的肝结肠转移瘤变得可切除——这可行吗？
Semin Oncol. 2005 Dec;32(6 Suppl 9):S118-22. doi: 10.1053/j.seminoncol.2005.04.030.

引用本文的文献

1
Patterns and resectability of colorectal cancer recurrences: outcome study within the COLOFOL trial.结直肠癌复发的模式和可切除性：COLOFOL 试验中的结果研究。
BJS Open. 2021 Jul 6;5(4). doi: 10.1093/bjsopen/zrab067.
2
A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer.基于免疫相关基因的 IV 期结直肠癌患者新型预后风险评分模型。
Biosci Rep. 2020 Oct 30;40(10). doi: 10.1042/BSR20201725.
3
Bioluminescence imaging of a tumor-selective, thymidine kinase-defective vaccinia virus Guang9 strain after intratumoral or intraperitoneal administration in mice.
肿瘤选择性、胸苷激酶缺陷型痘苗病毒Guang9株在小鼠瘤内或腹腔注射后的生物发光成像
Oncotarget. 2017 Sep 8;8(51):88708-88718. doi: 10.18632/oncotarget.20788. eCollection 2017 Oct 24.
4
Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis.使用mFOLFOX6联合帕尼单抗对伴有家族性腺瘤性息肉病的多发性结直肠癌不可切除肝转移进行转化治疗。
Int Surg. 2014 Nov-Dec;99(6):795-801. doi: 10.9738/INTSURG-D-13-00125.1.
5
Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619).肝切除术中胶原蛋白止血剂Sangustop®与载体结合纤维蛋白密封剂有效性的随机对照多中心试验（ESSCALIVER研究，NCT00918619）
Langenbecks Arch Surg. 2014 Aug;399(6):725-33. doi: 10.1007/s00423-014-1203-9. Epub 2014 Jun 1.
6
Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.新辅助化疗对可切除结直肠癌肝转移患者的疗效。
PLoS One. 2014 Jan 21;9(1):e86543. doi: 10.1371/journal.pone.0086543. eCollection 2014.
7
Minimal invasive surgery in treatment of liver metastases from colorectal carcinomas: case studies and survival rates.微创外科手术治疗结直肠癌肝转移：病例研究与生存率
BMC Surg. 2013;13 Suppl 2(Suppl 2):S45. doi: 10.1186/1471-2482-13-S2-S45. Epub 2013 Oct 8.
8
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?“转化化疗”真的能改善肝转移结直肠癌患者的生存吗？
World J Surg. 2014 Apr;38(4):936-46. doi: 10.1007/s00268-013-2305-1.
9
Influence of preoperative chemotherapy on CT volumetric liver regeneration following right hemihepatectomy.术前化疗对右半肝切除术后CT测量的肝脏体积再生的影响。
World J Surg. 2014 Feb;38(2):497-504. doi: 10.1007/s00268-013-2278-0.
10
Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival.肝切除术治疗初始不可切除结直肠转移瘤的治愈率：实际 5 年生存率分析。
J Gastrointest Surg. 2013 Feb;17(2):352-9. doi: 10.1007/s11605-012-2103-3. Epub 2012 Dec 8.